GMP manufacturing pitfalls that delay biologics production can increase costs, disrupt clinical timelines, and compromise regulatory readiness if not addressed early.
In biologics development, delays rarely come from a single dramatic failure. More often, they result from small oversights during process development that later become major bottlenecks under GMP conditions. Whether you are working with microbial or mammalian systems, understanding common GMP manufacturing pitfalls is essential to protect your timeline and your investment.
1. Process Design Not Built for Scale
One of the most frequent GMP manufacturing pitfalls is developing a process that performs well at laboratory scale but lacks scalability. Parameters such as oxygen transfer, mixing efficiency, and feeding strategies behave very differently when moving from small-scale reactors to production volumes.
In microbial production, insufficient oxygen transfer can reduce yields dramatically. In mammalian production, subtle shifts in shear stress or pH control may impact cell viability and product quality.
Avoiding this pitfall requires early scale-down models and development strategies aligned with future GMP manufacturing expectations. At 53Biologics, scalability is embedded from the beginning through our integrated Biologics Production Capabilities, ensuring upstream and downstream processes remain robust during transition.
2. Incomplete Regulatory Alignment during GMP Manufacturing
Another critical pitfall is assuming that regulatory requirements can be addressed only once the process is finalized. In reality, regulatory readiness must be incorporated during development.
International guidelines on Good Manufacturing Practices, emphasize documentation control, traceability and validated procedures from early stages.
Common regulatory-related delays include:
-
Insufficient characterization of raw materials
-
Incomplete validation of analytical methods
-
Poorly defined critical process parameters
-
Gaps in documentation during tech transfer
By integrating GMP principles into development, 53Biologics minimizes the risk of late-stage compliance corrections that can delay clinical manufacturing.
3. Underestimating Technology Transfer
Technology transfer is often treated as an administrative step. In reality, it is one of the most complex phases in biologics production. A poorly managed transfer can introduce variability, inconsistencies, and delays in GMP batch execution.
When sponsors engage a CDMO too late, knowledge gaps may surface. Assumptions made at research scale may not translate directly into GMP manufacturing conditions.
At 53Biologics, tech transfer is approached as a structured integration process rather than a simple data exchange. This ensures that process understanding, risk assessment and documentation are fully aligned before entering GMP manufacturing execution.
4. Platform Mismatch Before Moving to GMP Manufacturing
Selecting the wrong protein production platform can significantly delay biologics production. For example, a protein initially expressed in a microbial system may later require mammalian production to achieve proper folding or glycosylation. Such platform changes at advanced stages can reset development timelines.
A strategic evaluation of microbial production versus mammalian production early in the program reduces this risk. 53Biologics supports both platforms, enabling sponsors to select the most appropriate route based on molecule complexity, regulatory pathway, and commercial strategy.
This flexibility is particularly valuable for biotech companies transitioning from development to clinical manufacturing for the first time.
5. Weak Quality Systems Integration
Even when the science is sound, weak integration between development and quality systems can delay GMP manufacturing. Batch records, deviation handling and change control must function seamlessly.
A robust quality system does not simply react to problems. It anticipates them. At 53Biologics, quality management is embedded across development and manufacturing activities, supporting consistent and traceable biologics production.
How to Avoid GMP Manufacturing Pitfalls
Avoiding these GMP pitfalls requires proactive alignment between development, scale-up strategy, and regulatory planning. Key preventive measures include:
-
Designing processes with scalability in mind
-
Integrating GMP documentation standards early
-
Performing structured risk assessments
-
Engaging a biologics CDMO before clinical urgency arises
-
Selecting the appropriate production platform from the outset
GMP manufacturing is not merely a regulatory requirement. It is a strategic milestone that determines whether biologics production advances smoothly or encounters repeated setbacks.
Final Thoughts
GMP manufacturing pitfalls that delay biologics production are often preventable with the right planning and partnership. Early alignment between development and GMP expectations reduces risk, protects timelines, and supports regulatory confidence.
Having the correct CDMO by your side will guide you from development through GMP manufacturing, combining expertise in protein production, microbial production and mammalian production under a flexible and compliant framework.
If your program is approaching clinical manufacturing, now is the right time to evaluate potential risks and define a clear GMP roadmap.
About 53Biologics:
53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.
For more information or to speak with one of our experts email us at [email protected]
